| Date | Time | Source | Headline | Symbol | Company |
| 05/08/2007 | 8:30AM | PR Newswire (US) | Allos Therapeutics Reports First Quarter 2007 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/01/2007 | 1:21PM | PR Newswire (US) | Allos Therapeutics to Announce 2007 First Quarter Results on Tuesday, May 8 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 04/26/2007 | 8:00AM | PR Newswire (US) | Allos Therapeutics Appoints Dr. Jeffrey R. Latts to Its Board of Directors | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 04/19/2007 | 8:30AM | PR Newswire (US) | Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/20/2007 | 8:00AM | PR Newswire (US) | Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical Officer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/05/2007 | 7:00AM | PR Newswire (US) | Allos Therapeutics Reports Fourth Quarter and 2006 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/27/2007 | 8:00AM | PR Newswire (US) | Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/13/2007 | 8:00AM | PR Newswire (US) | Allos Therapeutics to Present at Upcoming Investor Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/02/2007 | 11:01AM | PR Newswire (US) | Allos Therapeutics Announces Closing of Common Stock Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/30/2007 | 6:00AM | PR Newswire (US) | Allos Therapeutics Announces Pricing of Underwritten Offering of 9,000,000 Shares of Common Stock | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/08/2007 | 3:19PM | PR Newswire (US) | Allos Therapeutics to Present at the 2007 JP Morgan Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/08/2007 | 7:05AM | PR Newswire (US) | Allos Therapeutics Appoints William R. Ringo to Its Board of Directors | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/08/2007 | 7:00AM | PR Newswire (US) | Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patien | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/11/2006 | 11:46AM | PR Newswire (US) | Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel An | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/20/2006 | 8:00AM | PR Newswire (US) | Allos Therapeutics Added to NASDAQ Biotech Index | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/10/2006 | 8:15AM | PR Newswire (US) | Updated Safety Analysis of Allos Therapeutics Phase 1/2 Study of PDX in Patients With Aggressive Lymphomas Demonstrates Decrease | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/09/2006 | 1:56PM | PR Newswire (US) | Allos Therapeutics Announces Presentation of Updated Results From Phase 1/2 Trial of PDX in Patients With Aggressive Lymphomas a | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/06/2006 | 12:00PM | PR Newswire (US) | Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemor | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/03/2006 | 7:30AM | PR Newswire (US) | Allos Therapeutics Reports Third Quarter 2006 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/01/2006 | 4:00PM | PR Newswire (US) | Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/31/2006 | 12:30PM | PR Newswire (US) | Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and PDX at Upcoming Scientific Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/23/2006 | 7:29AM | PR Newswire (US) | Allos Therapeutics Announces ENRICH Trial Update | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/03/2006 | 9:00AM | PR Newswire (US) | Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/29/2006 | 8:30AM | PR Newswire (US) | Allos Therapeutics to Present at Upcoming Investor Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/29/2006 | 8:00AM | PR Newswire (US) | Allos Therapeutics Initiates Pivotal Phase 2 Study of PDX in Patients With Peripheral T-cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/28/2006 | 8:00AM | PR Newswire (US) | Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Study of EFAPROXYN(TM) in Women with Brain Metastases Origin | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/07/2006 | 8:00AM | PR Newswire (US) | Allos Therapeutics Reports Second Quarter 2006 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/02/2006 | 8:30AM | PR Newswire (US) | Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Study of the Company's Novel Antifolate PDX in Pati | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/26/2006 | 9:00AM | PR Newswire (US) | FDA Grants Orphan Drug Designation to Allos Therapeutics' Novel Antifolate PDX for the Treatment of T-cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/14/2006 | 8:00AM | PR Newswire (US) | Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPR | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |